in

Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee 

With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. Aachen, Germany, 12 April 2021 – Today, Grünenthal has announced the acquisition… Source: RealWire Source Article

Written by HR Today

NautaDutilh Extends Relationship with Ascertus as Lead Software Integrator for the iManage Stack and Best-in-Class Support Partner

Barclays outlines policy to avoid burnout among junior bankers